Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

This study has been completed.
Sponsor:
Information provided by:
Bayside Health
ClinicalTrials.gov Identifier:
NCT00163631
First received: September 11, 2005
Last updated: October 3, 2006
Last verified: September 2005
  Purpose

Investigate vasoactive medicators in portal hypertension on stored sera


Condition
Portal Hypertension

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Cross-Sectional
Official Title: Relationship of Vasoactive Peptide Levels to Portal Pressure and Patient Outcomes in Patients With Hepatic Cirrhosis

Resource links provided by NLM:


Further study details as provided by Bayside Health:

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • portal hypertension

Exclusion Criteria:

  • Nil
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00163631

Locations
Australia, Victoria
Alfred Hospital
Melbourne, Victoria, Australia, 3181
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: William W Kemp, MBBS FRACP The Alfred
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00163631     History of Changes
Other Study ID Numbers: 4104
Study First Received: September 11, 2005
Last Updated: October 3, 2006
Health Authority: Australia: Human Research Ethics Committee

Additional relevant MeSH terms:
Hypertension
Hypertension, Portal
Fibrosis
Liver Cirrhosis
Vascular Diseases
Cardiovascular Diseases
Liver Diseases
Digestive System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on April 16, 2014